INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $718 | -18.1% | 13,783 | -0.5% | 0.06% | -13.5% |
| Q2 2023 | $877 | +16.9% | 13,858 | 0.0% | 0.07% | +8.8% |
| Q1 2023 | $750 | +1.2% | 13,858 | -1.1% | 0.07% | -2.9% |
| Q4 2022 | $741 | -99.9% | 14,008 | 0.0% | 0.07% | +6.1% |
| Q3 2022 | $652,000 | -30.8% | 14,008 | -15.1% | 0.07% | -25.8% |
| Q2 2022 | $942,000 | -29.5% | 16,508 | -24.5% | 0.09% | -17.6% |
| Q1 2022 | $1,337,000 | -28.8% | 21,858 | -39.1% | 0.11% | -23.9% |
| Q4 2021 | $1,879,000 | +54.0% | 35,908 | +9.7% | 0.14% | +36.5% |
| Q3 2021 | $1,220,000 | -43.3% | 32,738 | -37.9% | 0.10% | -42.9% |
| Q2 2021 | $2,153,000 | +20.2% | 52,738 | -0.1% | 0.18% | +9.6% |
| Q1 2021 | $1,791,000 | +6.7% | 52,788 | 0.0% | 0.17% | +1.8% |
| Q4 2020 | $1,679,000 | +23.9% | 52,788 | 0.0% | 0.16% | +11.6% |
| Q3 2020 | $1,355,000 | +10.9% | 52,788 | +10.9% | 0.15% | +0.7% |
| Q2 2020 | $1,222,000 | +67.2% | 47,588 | 0.0% | 0.14% | +36.8% |
| Q1 2020 | $731,000 | -50.0% | 47,588 | +11.7% | 0.11% | -38.7% |
| Q4 2019 | $1,461,000 | +271.8% | 42,588 | -19.0% | 0.17% | +246.0% |
| Q3 2019 | $393,000 | -42.5% | 52,588 | 0.0% | 0.05% | -43.2% |
| Q2 2019 | $683,000 | +6.6% | 52,588 | 0.0% | 0.09% | -1.1% |
| Q1 2019 | $641,000 | +8.1% | 52,588 | +1.0% | 0.09% | -5.3% |
| Q4 2018 | $593,000 | -49.4% | 52,060 | -3.7% | 0.09% | -40.9% |
| Q3 2018 | $1,173,000 | +22.8% | 54,060 | 0.0% | 0.16% | +14.4% |
| Q2 2018 | $955,000 | -16.1% | 54,060 | 0.0% | 0.14% | -18.7% |
| Q1 2018 | $1,138,000 | +45.3% | 54,060 | 0.0% | 0.17% | +46.2% |
| Q4 2017 | $783,000 | +209.5% | 54,060 | +236.6% | 0.12% | +178.6% |
| Q3 2017 | $253,000 | +27.1% | 16,060 | 0.0% | 0.04% | +23.5% |
| Q2 2017 | $199,000 | -53.0% | 16,060 | -38.4% | 0.03% | -54.7% |
| Q1 2017 | $423,000 | +153.3% | 26,060 | +135.6% | 0.08% | +158.6% |
| Q4 2016 | $167,000 | -72.8% | 11,060 | -72.6% | 0.03% | -74.1% |
| Q3 2016 | $615,000 | -52.7% | 40,350 | +20.4% | 0.11% | -54.7% |
| Q2 2016 | $1,300,000 | +33.7% | 33,500 | -4.1% | 0.25% | +28.6% |
| Q1 2016 | $972,000 | -44.4% | 34,950 | +7.6% | 0.19% | -44.2% |
| Q4 2015 | $1,747,000 | +31.5% | 32,475 | -2.2% | 0.34% | +30.3% |
| Q3 2015 | $1,329,000 | – | 33,200 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |